Pay in 4 interest-free payments of $9.00 Learn more
Ships within 48 hours · Estimated delivery Oct 12 - Oct 17
120(8):1668-77
Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor
RA190 stabilized targets of human papillomavirus (HPV) E6 oncoprotein
inhibits Nedd4
increases the expression of p62 and Nrf2 and inactivates Keap1 in HN3-rslR cells
GSK-J1 - H3K27 Histone Demethylases UTX and JMJD3 Inhibitor. CAS# 1373422-53-7 size:2mg solid 120(8):1668-77GSK J1, CAS No. 1373422 53 7, is the first selective and potent inhibitor of the H3K27 histone demethylases UTX and JMJD3. H3K27 methylations play important roles in regulating gene expression through the polycomb repressive complex (PRC1 or PRC2). This epigenetic mark can be demethylated by lysine demethylase (KDM) UTX and JMJD3, which play important roles in cellular differentiation, development and cancer. In relevant biological assays, GSK J1 was
US$ 79.00
US$ 187.00
US$ 40.00
US$ 149.99